This case will help you understand:
How companion diagnostic strategies can help to competitively reshape therapy markets.
The way one-size-fits-all therapies compete with targeted therapies in the marketplace under unanticipated rules.
Research of analogous therapy markets suggests that associated companion diagnostic strategies can also serve to competitively reshape overall therapy areas.
Oncology, infectious disease and cardiovascular markets are at various stages of a shift towards therapy targeting. Targeted therapies will eventually be competing against each other for similar, disparate or overlapping niche markets.
Understand where and how personalized medicine provides opportunities to reshape the therapy market.
Revise and standardise Dx planning and strategy development.
Consider using the Options for Test index (OFTi) to provide a standardized and rapid way to assess a personalized medicine fit across a therapy pipeline.